Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma

Published:2015-12 Issue:12 Volume:15 Page:761-765
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Aguiar-Bujanda David,Blanco-Sánchez María Jesús,Hernández-Sosa María,Galván-Ruíz Saray,Hernández-Sarmiento Samuel,Saura-Grau Salvador,Bohn-Sarmiento Uriel

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference22 articles.

1. Rituximab therapy in malignant lymphoma;Coiffier;Oncogene,2007

2. Rituximab: current status as therapy for malignant and benign hematologic disorders;Abdulla;BioDrugs,2012

3. The late adverse events of rituximab therapy—rare but there!;Ram;Leuk Lymphoma,2009

4. Neutropenia in patients treated with rituximab;Benyunes;N Engl J Med,2003

5. Delayed-onset neutropenia associated with rituximab therapy;Chaiwatanatorn;Br J Haematol,2003

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Update on the Incidence, Risk Factors and Mechanisms of Rituximab- Associated Neutropenia;Archives of Medical Science;2022-09-15

2. Late-onset toxicities of monoclonal antibodies in cancer patients;Immunotherapy;2022-09

3. Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine;Frontiers in Immunology;2022-01-10

4. Risk Factors for Neutropenia after the First Cycle of Chemotherapy for Non-Hodgkin Lymphoma;European Journal of Medical and Health Sciences;2021-12-07

5. Myeloid maturation arrest and severe late-onset neutropenia following ocrelizumab therapy in a patient with multiple sclerosis: A case report and review of the literature;Neuroimmunology Reports;2021-12